A study found that rapid HIV testing during labor can provide accurate results within 66 minutes, enabling women to receive antiretroviral prophylaxis. The study also showed higher test acceptance among younger women and those with limited prenatal care, highlighting the importance of early testing for pregnant women.
A randomized, controlled clinical trial found that a targeted HIV prevention intervention significantly reduced consistent condom use and risky sexual behaviors in high-risk African-American adolescent girls. The intervention emphasized ethnic and gender pride, HIV knowledge, communication, and healthy relationships.
Researchers found that using growth-hormone-releasing hormone (GHRH) therapy can increase normal growth hormone production and regulation in men with HIV lipodystrophy. This approach resulted in improved body composition, reduced fat deposits, and better cardiovascular health outcomes.
A study found that gender-and culturally-tailored HIV prevention programs reduced HIV incidence among African American teen girls. The interventions also showed promise in reducing chlamydia cases and promoting healthier relationships.
A randomized trial found that two short drug regimens for infants at birth reduced mother-to-child transmission of HIV compared to a single regimen. The study suggests several options for prevention, including voluntary counseling and testing, standard NVP prophylaxis, and postexposure prophylaxis.
A three-year clinical trial comparing tenofovir DF and stavudine found both treatments to be equally effective in treating HIV, but tenofovir DF had fewer toxic outcomes related to cholesterol levels, lipodystrophy, and peripheral neuropathy. The study involved over 600 patients across the US, South America, and Europe.
A randomized trial found that tenofovir disoproxil fumarate achieved high viral load suppression rates, comparable to stavudine-based regimens. Tenofovir DF was also associated with lower toxicity and better lipid profiles.